
|Videos|November 16, 2017
Dr. Lara on the FDA Approval of Adjuvant Sunitinib in RCC
Author(s)Primo N. Lara Jr, MD
Primo N. Lara Jr, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the FDA approval of adjuvant sunitinib (Sutent) for high-risk patients with renal cell carcinoma (RCC).
Advertisement
Primo N. Lara Jr, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the FDA approval of adjuvant sunitinib (Sutent) for high-risk patients with renal cell carcinoma (RCC).
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Palbociclib Plus Trastuzumab, With/Without Pertuzumab, and ET as Maintenance in HR+, HER2+ Metastatic Breast Cancer
2
FDA Approves Sacituzumab Govitecan Monotherapy and In Combination With Pembrolizumab in Frontline TNBC
3
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
4
Perioperative Pembrolizumab/Enfortumab Vedotin Approved in Europe for Cisplatin-Ineligible MIBC
5




















































































